Jon M. Wigginton

Hematology | Oncology

6244 Jefferson Blvd
Frederick, MD 21703

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 07, 2023

The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.

The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.

Journal: Journal for immunotherapy of cancer

Published: April 15, 2020

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.

Journal: Journal for immunotherapy of cancer

Published: April 01, 2020

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.

Journal: The Lancet. Oncology

Published: March 09, 2020

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: November 17, 2016

Combination immunotherapy: a road map.

Combination immunotherapy: a road map.

Journal: Journal for immunotherapy of cancer

Published: October 28, 2016

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 22, 2015

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 25, 2015

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 05, 2014

Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor.

Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor.

Journal: Cancer immunology research

Published: January 14, 2014

Professor Jon Wigginton: where we are standing in immunotherapy.

Professor Jon Wigginton: where we are standing in immunotherapy.

Journal: Chinese clinical oncology

Published: December 01, 2013

Nivolumab plus ipilimumab in advanced melanoma.

Nivolumab plus ipilimumab in advanced melanoma.

Journal: The New England journal of medicine

Published: June 04, 2013

Showing 1-12 of 15

Last Updated: 09/26/2026